Abstract

The present invention concerns a polymeric composition with improved rheological properties, comprising at least one polyanionic polysaccharide, or a derivative thereof, and a polyaminosaccharide chosen from chitosan, functionalised chitosan and salts thereof. The invention furthermore concerns methods for the preparation of said polymeric composition and uses thereof.

IPC Classes  ?

• C08L 5/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• A61L 27/20 - Polysaccharides
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• C08B 37/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

The present invention concerns a polymeric composition with improved rheological properties, comprising at least one polyanionic polysaccharide, or a derivative thereof, and a polyaminosaccharide chosen from chitosan, functionalised chitosan and salts thereof. The invention furthermore concerns methods for the preparation of said polymeric composition and uses thereof.

IPC Classes  ?

• C08B 37/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• C08L 5/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof

Abstract

A crosslinked polymer of functionalized hyaluronic acid, or derivative thereof, is disclosed, as well as a process for its preparation and its use as a biomaterial and as an ingredient in pharmaceutical compositions. The use of this crosslinked polymer in the treatment of disorders ascribable to altered galectin expression, is also disclosed.

IPC Classes  ?

• C08B 37/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A crosslinked polymeric material is described which comprises at least one functionalized chitosan, and optionally at least one polyanionic polysaccharide, as well as a process for the preparation thereof and for the use thereof as a biomaterial and as an ingredient in pharmaceutical compositions. The use of this crosslinked polymeric material in the treatment of pathologies ascribable to altered galectin expression is also described.

IPC Classes  ?

• C08B 37/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• C08J 3/075 - Macromolecular gels
• C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
• C08L 5/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• A61K 8/73 - Polysaccharides
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61L 27/20 - Polysaccharides

Goods & Services

Pharmaceuticals; Dermatological pharmaceutical products; Chemico-pharmaceutical preparations; Food supplements; Medicated food supplements; Pharmaceutical creams; Medicated creams; Antibiotic creams. Medical instruments; Medical implants. Scientific research and development; Scientific services and design relating thereto; Science and technology services; Scientific testing services; Scientific laboratory services; Conducting of scientific studies; Research on the subject of pharmaceuticals; Pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Provision of information and data relating to medical and veterinary research and development.

Abstract

The present invention discloses a functionalized hyaluronic acid or a derivative thereof, as well as a process for the preparation thereof, and the use thereof as a biomaterial and as an ingredient in pharmaceutical compositions. The present invention furthermore discloses the use of said functionalized hyaluronic acid or a derivative thereof in the treatment of pathologies ascribable to altered galectin expression.

IPC Classes  ?

• C08B 37/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• A61K 31/728 - Hyaluronic acid
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A neutral salt consisting of a polyaminosaccharide cation and an anion, as well as a procedure for the preparation of the neutral salt and uses thereof as a biomaterial and as an ingredient in pharmaceutical compositions are disclosed. Indeed, said neutral salt has surprisingly exhibited high water-solubility and high purity, the preparation procedure having minimised the content of high-risk contaminants in the final product and reduced reaction and purification times.

IPC Classes  ?

• C08B 37/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• A61K 31/722 - ChitinChitosan
• A61K 31/734 - Alginic acid
• A61K 31/737 - Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
• A61K 31/765 - Polymers containing oxygen
• A61K 33/42 - PhosphorusCompounds thereof
• A61K 38/39 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Abstract

A crosslinked polymer of functionalized hyaluronic acid, or derivative thereof, is disclosed, as well as a process for its preparation and its use as a biomaterial and as an ingredient in pharmaceutical compositions. The use of this crosslinked polymer in the treatment of disorders ascribable to altered galectin expression, is also disclosed.

IPC Classes  ?

• C08B 37/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• A61K 31/728 - Hyaluronic acid

Abstract

The present application describes polysaccharide compositions that can be used as modulators of cell proliferation processes and their use in tissue repair with fibrotic process inhibition. These modulation properties can be usefully used in tissue repair for the prevention of fibrotic processes and/or tissue adhesions in traumatic, post-surgical and chronic fibrotic processes associated to autoimmune diseases.

IPC Classes  ?

• A61K 31/728 - Hyaluronic acid
• A61P 41/00 - Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61K 31/722 - ChitinChitosan

Abstract

A composition is disclosed comprising at least one cannabinoid receptor type-2 selective agonist, at least one substance having antioxidant properties, and at least one tissue function modulator. Said composition has proved to effectively treat diseases characterised by high oxidative stress, inflammatory state, and tissue dysfunction.

IPC Classes  ?

• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Goods & Services

Pharmaceuticals; Neutraceutical preparations for humans; Nutraceutical preparations for therapeutic or medical purposes; Topical gels for medical and therapeutic use; Injectable pharmaceuticals.

Abstract

The present invention discloses a functionalized hyaluronic acid or a derivative thereof, as well as a process for the preparation thereof, and the use thereof as a biomaterial and as an ingredient in pharmaceutical compositions. The present invention furthermore discloses the use of said functionalized hyaluronic acid or a derivative thereof in the treatment of pathologies ascribable to altered galectin expression.

IPC Classes  ?

• C08B 37/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof

Abstract

The present invention discloses a pharmaceutical composition comprising at least one bioactive substance and at least one neutral salt consisting of a polyamino-saccharide cation and an anion, for use in the treatment of articular tissues affected by arthropathies, wherein said pharmaceutical composition reduces expression of the key receptors involved in the genesis the inflammatory cascade and efficaciously maintains performance for a prolonged period of time.

IPC Classes  ?

• A61K 31/726 - Glycosaminoglycans, i.e. mucopolysaccharides
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 31/727 - HeparinHeparan
• A61K 31/728 - Hyaluronic acid
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Goods & Services

Pharmaceuticals; Neutraceutical preparations for humans; Nutraceutical preparations for therapeutic or medical purposes; Topical gels for medical and therapeutic use; Injectable pharmaceuticals; all the aforementioned products relating to antiinflammatory products; none of the aforementioned products are intended for or relate to antipsychotic medications, or gastrointestinal disorders, particularly nausea and vomiting.

Goods & Services

Pharmaceuticals; Neutraceutical preparations for humans; Nutraceutical preparations for therapeutic or medical purposes; Topical gels for medical and therapeutic use; Injectable pharmaceuticals.

Abstract

A neutral salt consisting of a polyaminosaccharide cation and an anion, as well as a procedure for the preparation of the neutral salt and uses thereof as a biomaterial and as an ingredient in pharmaceutical compositions are disclosed. Indeed, said neutral salt has surprisingly exhibited high water- solubility and high purity, the preparation procedure having minimised the content of high-risk contaminants in the final product and reduced reaction and purification times.

IPC Classes  ?

• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 31/722 - ChitinChitosan
• C08B 37/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof

Goods & Services

Food supplements; Food supplements in beverage form; Preparations for dietary use; Dietetic food and substances adapted for medical use; Special dietetic food adapted for medical use; Pharmaceuticals and medical preparations, in particular for preventing and/or treating disorders and diseases in the urological sector; Neutraceutical preparations for humans.

Goods & Services

Syringes pre-filled with pharmaceutical compositions for human and veterinary use adapted for loco-regional administration of the aforesaid compositions; pre-filled syringes with pharmaceutical compositions for treatment of osteoarticular disorders, of bone and joint pathologies, of musculoskeletal pathologies and of degenerative and chronic inflammatory pathologies; pharmaceutical products for human and veterinary uses; pharmaceutical products and medical preparations for the treatment of bone and joint pathologies; pharmaceutical products and medical preparations for the treatment of osteoarticular disorders; pharmaceutical products and medical preparations for the treatment of vertebral-spinal pathologies and disorders; pharmaceutical products and medical preparations for the treatment of musculoskeletal pathologies; pharmaceutical products and medical preparations for the treatment of degenerative and chronic inflammatory pathologies; pharmaceutical products and medical preparations for the treatment of inflammatory pathologies due to rheumatic disorders, or trauma or auto-immune conditions. Medical devices, namely syringes for loco-regional administration of pharmaceutical compositions for human and veterinary use.

Abstract

The present application describes compositions that can be used for the controlled release of pharmacological active ingredients from a viscoelastic aqueous polysaccharide matrix, and their potential use in the treatment of different stages of musculoskeletal diseases. The combination of drug release modulation and the viscoelastic nature of the composition makes possible the use thereof in the treatment of acute and chronic phases of musculoskeletal diseases characterized by an inflammatory state, and where a therapeutic effect and a viscosupplemental contribution are required.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Goods & Services

Chemical compositions and materials for use in cosmetics; Chemical and organic compositions and substances for treatment of leather and textile; Industrial chemicals. Pharmaceuticals; Dermatological pharmaceutical products; Chemico-pharmaceutical preparations; Food supplements; Medicated food supplements; Pharmaceutical creams; Medicated creams; Antibiotic creams; all aforesaid goods not meant for ophthalmology.

Goods & Services

Pharmaceuticals; Dermatological pharmaceutical products; Chemico-pharmaceutical preparations; Food supplements; Medicated food supplements; Pharmaceutical creams; Medicated creams; Antibiotic creams. Medical instruments; Medical implants. Scientific research and development; Scientific services and design relating thereto; Science and technology services; Scientific testing services; Scientific laboratory services; Conducting of scientific studies; Research on the subject of pharmaceuticals; Pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Provision of information and data relating to medical and veterinary research and development.

Abstract

The present application describes polysaccharide compositions that can be used as modulators of cell proliferation processes and their use in tissue repair with fibrotic process inhibition. These modulation properties can be usefully used in tissue repair for the prevention of fibrotic processes and/or tissue adhesions in traumatic, post-surgical and chronic fibrotic processes associated to autoimmune diseases.

IPC Classes  ?

• A61K 31/722 - ChitinChitosan
• A61K 31/728 - Hyaluronic acid
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61P 17/12 - Keratolytics, e.g. wart or anti-corn preparations
• A61P 19/00 - Drugs for skeletal disorders
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue

Abstract

It is disclosed a biocomposite of hydroxyapatite on graphene oxide sheets and its use for bone tissue engineering applications, such as bone repair, bone augmentation, as well as coating of biomedical implants. Processes for preparing said biocomposites are also described.

IPC Classes  ?

• A61L 27/08 - Carbon
• A61L 27/12 - Phosphorus-containing materials, e.g. apatite

Abstract

Nanoassembled complexes of nucleic acids, avidin and biotinylated compounds functionalized to make them suitable for delivering and releasing drugs are described. These nanoassembled complexes consist of central poly-avidin nucleus, i.e. nucleus formed from the self-assembling of tetrameric avidin units on oligonucleotide sequences of nucleic acids, on which biotinylated compounds are further auto-assembled through high-affinity interactions between the avidin of the central nucleus and the biotin of the biotinylated compounds. The biotinylated compounds are functionalized so as to bind drugs with a reversible bond, allowing the delivery thereof and a controlled release.

IPC Classes  ?

• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents

Goods & Services

Pharmaceutical preparations and biomedical aids for human and veterinary use; Biomedical aids pre-loaded with pharmaceutical and biomedical compositions for locoregional implants. Biomedical devices designed for locoregional implants pre-loaded with pharmaceutical and biomedical compositions for human and veterinary use.

Goods & Services

Pharmaceutical and veterinary preparations for surgical, plastic surgery, dental and orthopaedic purposes; Bone cement for surgical, plastic surgery, dental and orthopaedic purposes. Apparatus and instruments for surgical, plastic surgery, dental and orthopaedic purposes; Artificial materials for surgical, plastic surgery, dental and orthopaedic implants.

Goods & Services

Biopolymer compositions for scientific purposes; Biopolymer compositions for industrial purposes; Biopolymer compositions for cosmetic purposes. Biopolymer compositions for pharmaceutical purposes; Biopolymer compositions for medical and veterinary purposes.

Goods & Services

Pharmaceutical and veterinary preparations for intra-articular use.

Goods & Services

Chemical compounds of scientific purposes; Chemicals used in industry. Chemical compounds for pharmaceutical use; Chemical compounds for medical and veterinary purposes.

Goods & Services

Dietetic supplements adapted for medical use; Dietary supplements for human and veterinary use.

Goods & Services

Pharmaceutical preparations for orthopaedic and dermocosmetic use; Dietetic supplements adapted for medical use; Dietary supplements for human and veterinary use. Medical devices and instruments for orthopaedic and spinal use, namely syringes and cannulae. Scientific and technological services and research and design relating thereto for medical and veterinary purposes.